A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Bibliographic Details
Title:	A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)
Authors:	Leng, Xiaomei, Leszczyński, Piotr, Jeka, Slawomir, Liu, Shengyun, Liu, Huaxiang, Miakisz, Malgorzata, Gu, Jieruo, Kilasonia, Lali, Stanislavchuk, Mykola, Yang, Xiaolei, Zhou, Yinbo, Dong, Qingfeng, Mitroiu, Marian, Addison, Janet, Rezk, Mourad F., Zeng, Xiaofeng
Source:	Arthritis Research & Therapy; 9/7/2024, Vol. 26 Issue 1, p1-9, 9p
Database:	Complementary Index